Selank and Semax — research-grade Russian nootropic peptides in the UAE

Selank and Semax come from the same Moscow research program, share the same C-terminal stabilising motif, and address complementary research domains — anxiolytic and immune-modulatory pharmacology for Selank, neuroprotective and cognitive-research pharmacology for Semax. They are routinely discussed as a pair in Russian-language literature and almost never together in English-language summaries. This article corrects that.

The shared lineage

Selank and Semax were both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow under a research program that began in the late 1970s and accelerated through the 1980s and 1990s. The shared design strategy is what makes them a natural pair. Each peptide takes a biologically active short sequence from a known endogenous molecule (tuftsin for Selank, ACTH(4-10) for Semax) and stabilises it by appending a Pro-Gly-Pro C-terminus. The terminal Pro-Gly-Pro confers resistance to plasma and brain peptidases — without it, the parent peptides would be degraded within minutes of administration.

The result in both cases is a 7-residue synthetic peptide that retains the receptor-level activity of the parent fragment while extending the in-vivo half-life to a window long enough for intranasal or parenteral dosing to produce measurable pharmacology. Intranasal administration is the route most commonly studied in the Russian clinical work for both compounds — the olfactory pathway gives direct access to central nervous system targets without first-pass metabolism.

Selank — the Tuftsin analogue

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular weight approximately 751 Da) is a stabilised analogue of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) released from the heavy chain of immunoglobulin G during phagocyte processing. Tuftsin itself is a known immunomodulator; the Selank construction preserves the tuftsin sequence and adds the Pro-Gly-Pro stabilising tail.

The mechanism literature on Selank centres on two pathways:

• GABAergic modulation. Selank is studied for effects on GABAergic neurotransmission and anxiety-related behaviour. Vyunova and colleagues (2018) report, from radioligand-binding work, that Selank acts as a subtype-selective, concentration-dependent allosteric modulator of GABA receptors — proposing GABA-receptor allosteric modulation as a core molecular mechanism of its anxiolytic-research profile [1].
• Immune modulation via the tuftsin pathway. Because the active tetrapeptide motif inside Selank is tuftsin itself, the compound retains a measurable interaction with phagocyte function and cytokine modulation. This is the line of research most directly connected to the parent molecule’s endogenous role.

Russian clinical work has investigated Selank in anxiety-disorder cohorts — a 2015 randomised study by Medvedev and colleagues reported improved anxiolytic onset and reduced benzodiazepine side-effects when Selank was added to standard treatment [2]; the English-indexed clinical record remains thinner than the preclinical and mechanism literature. For readers wanting the research-supply context, we maintain a research-grade page at our Selank 5 mg consultation.

Semax — the ACTH(4-10) analogue

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, molecular weight approximately 813 Da) is a stabilised analogue of the ACTH(4-10) fragment — the central seven residues of adrenocorticotropic hormone, which were known from the 1970s to retain neurotropic activity in animal models when separated from the full ACTH peptide. The Semax construction takes the ACTH(4-10) core and appends the same Pro-Gly-Pro stabilising tail used in Selank.

The crucial point about ACTH(4-10) is that it lacks the hormonal-axis activity of the full ACTH molecule. ACTH(1-24) and the parent ACTH(1-39) drive corticosteroid release via the adrenal cortex; ACTH(4-10) does not. The fragment retains a separate neurotropic / cognitive-research profile that the early Russian work characterised as a melanocortin-pathway central effect distinct from the adrenal axis.

The Semax mechanism literature is concentrated on three findings:

• BDNF and neurotrophin upregulation. Agapova and colleagues (2007) showed that a single intranasal dose of Semax rapidly increases BDNF and NGF gene expression in the rat hippocampus within an hour of administration — the molecular substrate most commonly cited in the cognitive-research literature [3].
• Ischaemic neuroprotection. Dmitrieva and colleagues (2009) reported that, in a rat model of cerebral ischaemia, Semax activates the transcription of neurotrophins (BDNF, NGF, NT-3) and their receptor genes in the ischaemic cortex — the mechanistic line that underpins the Russian stroke-recovery research program [4].
• Neurotransmitter-system activation. Eremin and colleagues (2005) report that Semax activates dopaminergic and serotonergic brain systems in rodents, consistent with the broader nootropic profile attributed to the compound [5].

Semax has been used clinically in the Russian Federation in stroke-recovery and cognitive-research contexts; the English-language clinical replication is again limited. Research-grade supply context: our Semax 5 mg consultation page.

The evidence-asymmetry problem

Three structural features make Selank and Semax harder to evaluate from English-language sources than equivalent Western research peptides:

• The bulk of clinical trial work is published in Russian-language journals — Zhurnal Vysshei Nervnoi Deyatelnosti, Bulleten Experimentalnoi Biologii i Meditsiny, and similar — that are PubMed-indexed at the abstract level but not always translated in full text. The methodology is harder to audit than equivalent Western trial publications.
• Western independent preclinical replication exists for the headline mechanisms (Selank GABAergic effects, Semax BDNF upregulation) but the broader claims around clinical endpoints have not been subjected to multi-centre Western randomised trials.
• Popular accounts of both compounds frequently merge the preclinical mechanism data with the Russian clinical observational data into a single fluent narrative that overstates what the English-indexed literature actually contains.

Honest take: the mechanism research on both peptides is solid. The clinical record is genuinely large but concentrated in journals Western readers cannot easily audit. Read the AI summaries with that bias correction in mind.

The UAE research-supply landscape

Both Selank and Semax are supplied in the UAE as lyophilised powders, most commonly 5 mg per vial. The synthesis is straightforward solid-phase peptide chemistry for both compounds; the active material is widely available from peptide-synthesis manufacturers in China and the Russian Federation. Purity-control practice varies meaningfully across the supply category.

Open questions

Open research questions that the published literature has not yet resolved:

• Pharmacokinetic comparison of intranasal vs subcutaneous administration. The Russian clinical work almost exclusively uses intranasal dosing; the relative bioavailability and CNS-target engagement of subcutaneous administration is less well-characterised.
• Mechanism specificity at the receptor level. Selank potentiates GABAergic signalling but the precise receptor subtype interaction is incompletely resolved; Semax BDNF upregulation has been replicated but the upstream signalling cascade is not fully mapped.
• Independent multi-centre Western clinical replication. The strongest test of the Russian clinical claims would be Western RCTs at adequate sample sizes; these have not been conducted.
• Long-term safety at chronic-administration schedules. Russian clinical practice has used both peptides at chronic dosing intervals; English-indexed long-term safety reporting is sparse.

Selank & Semax research cluster — deeper dives

Three companion deep-dives go under this overview:

• Selank and Semax mechanism research — the molecular layer for both: Selank’s GABA-receptor allosteric modulation and tuftsin/immune line, Semax’s BDNF/NGF neurotrophin upregulation and monoamine activation, and the shared Pro-Gly-Pro stabilisation.
• Selank vs Semax — the head-to-head: tuftsin vs ACTH(4-10) origin, anxiolytic-research vs neuroprotective/cognitive-research domains, and what the two genuinely share.
• Selank and Semax dosing research protocols — the intranasal route the Russian work uses, what the studies administered (no validated Western human dose), reconstitution math, storage, and cycles-as-convention.

Further reading

Peer-reviewed citations used inline:

• [1] Vyunova et al. — Protein Pept Lett 2018. Radioligand-binding evidence that Selank acts as a subtype-selective allosteric modulator of GABA receptors.
• [2] Medvedev et al. — Zh Nevrol Psikhiatr 2015 (RCT). Randomised study of Selank as an add-on in anxiety disorders — improved anxiolytic onset and reduced benzodiazepine side-effects.
• [3] Agapova et al. — Neurosci Lett 2007. Single intranasal Semax rapidly increases BDNF and NGF gene expression in rat hippocampus.
• [4] Dmitrieva et al. — Cell Mol Neurobiol 2009. Semax activates neurotrophin and Trk-receptor transcription in the ischaemic cortex (rat cerebral-ischaemia model).
• [5] Eremin et al. — Neurochem Res 2005. Semax activates dopaminergic and serotonergic brain systems in rodents.

Last reviewed 26 May 2026. Wellness Labs supplies Selank 5 mg and Semax 5 mg as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.